

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Seipert Christopher J.</u> _____ (Last) (First) (Middle) PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 1305 O'BRIEN DRIVE _____ (Street) MENLO CA 94025 PARK _____ (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 04/01/2020	3. Issuer Name and Ticker or Trading Symbol <u>PACIFIC BIOSCIENCES OF CALIFORNIA, INC. [PACB]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) VP, Sales, Service & Support	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	66,329 ⁽¹⁾	D	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Option (right to buy)	(2)	07/19/2020	Common Stock	2,000	12.74	D	
Stock Option (right to buy)	(2)	05/16/2021	Common Stock	5,000	11.7	D	
Stock Option (right to buy)	(2)	06/15/2021	Common Stock	5,000	11.64	D	
Stock Option (right to buy)	(2)	11/15/2021	Common Stock	20,000	3.3	D	
Stock Option (right to buy)	(2)	11/15/2023	Common Stock	20,000	4.07	D	
Stock Option (right to buy)	(2)	08/15/2024	Common Stock	14,500	5.18	D	
Stock Option (right to buy)	(2)	02/17/2025	Common Stock	1,000	6.91	D	
Stock Option (right to buy)	(2)	12/15/2025	Common Stock	30,000	10.07	D	
Stock Option (right to buy)	(2)	02/16/2026	Common Stock	18,000	8.9	D	
Stock Option (right to buy)	03/15/2017 ⁽³⁾	02/15/2027	Common Stock	55,000	5.27	D	
Stock Option (right to buy)	03/15/2018 ⁽³⁾	02/15/2028	Common Stock	50,000	2.54	D	

Explanation of Responses:

- Includes 50,000 shares represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of the Issuer subject to the applicable vesting schedule, provided that the Reporting Person continues to be a Service Provider through each vesting date.
- The shares subject to the option are fully vested and exercisable.
- One forty-eighth (1/48) of the shares subject to the option vests monthly over a four year period, provided that the Reporting Person is a service provider through each vesting date.

Remarks:

/s/ Christopher J. Seipert 04/02/2020

** Signature of Reporting

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.